bioAffinity Technologies, Inc. (BIAF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has a cash flow conversion efficiency ratio of -0.352x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.56 Million) by net assets ($7.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of bioAffinity Technologies, Inc. for the company's overall valuation and market capitalisation.
bioAffinity Technologies, Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how bioAffinity Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
bioAffinity Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their cash flow conversion efficiency. Explore cash flow quality index of bioAffinity Technologies, Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atossa Genetics Inc
NASDAQ:ATOS
|
-0.121x |
|
Mhethanol Co. Ltd.
KO:023150
|
0.081x |
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IS:SANEL
|
-0.255x |
|
Austin Gold Corp
NYSE MKT:AUST
|
-0.013x |
|
Metacon AB
ST:META
|
-0.611x |
|
Genolution Inc.
KQ:225220
|
-0.013x |
|
Sama Resources Inc.
V:SME
|
-0.002x |
|
POZZI MILANO S.P.A.
F:7TL
|
N/A |
Annual Cash Flow Conversion Efficiency for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of bioAffinity Technologies, Inc. from 2019 to 2025. View BIAF live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.28 Million | $-9.33 Million | -1.282x | +54.09% |
| 2024-12-31 | $2.60 Million | $-7.26 Million | -2.792x | -124.51% |
| 2023-12-31 | $4.86 Million | $-6.04 Million | -1.244x | -237.35% |
| 2022-12-31 | $11.04 Million | $-4.07 Million | -0.369x | -384.08% |
| 2021-12-31 | $-15.79 Million | $-2.05 Million | 0.130x | -11.41% |
| 2020-12-31 | $-15.07 Million | $-2.21 Million | 0.146x | -76.26% |
| 2019-12-31 | $-4.04 Million | $-2.49 Million | 0.617x | -- |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more